대한뉴팜

Daehan New Pharm has launched a new product, “Super Neofen”, developed to address swine pleuropneumonia, a contagious livestock disease. Swine pleuropneumonia, which frequently occurs during the winter season, is a bacterial infection that causes considerable damage to pig farms worldwide and has until now relied primarily on vaccination for prevention. Following years of research, “Super Neofen”, a newly developed therapeutic agent, has completed new drug registration with the Animal and Plant Quarantine Agency after passing safety and efficacy verification through domestic clinical trials.

“Super Neofen” is a medication that strengthens the immune system to fight against Actinobacillus pleuropneumoniae, the causative agent of swine pleuropneumonia. It is a specialized treatment combining three active ingredients—Florfenicol, an antibiotic effective for respiratory diseases in pigs; Acetaminophen, providing antipyretic, analgesic, and anti-inflammatory effects; and Bromhexine, acting as an antitussive and expectorant. This combination delivers rapid therapeutic effects for both acute and chronic respiratory conditions.

Clinical and field trials in domestic farms have shown that while the antibacterial activity of “Super Neofen” was similar to single-agent Florfenicol products, the treatment period was significantly shorter when administered compared to other formulations. The product allows simultaneous administration of the three components, making it more convenient, economical, and efficient for farmers by improving treatment outcomes, reducing labor, and enhancing productivity.

Starting this month, Daehan New Pharm will begin full-scale distribution of “Super Neofen” and expand its domestic supply network aggressively. The product’s composition patent (Application No. 10-2017-0058616) has been successfully filed, and global market entry is planned for countries including the United States, China, and Russia.